Basque enterprise blog Funding

Today Columbus Venture Partners announces the creation of Syngoi Technologies, a biotechnology company engaged in the production of synthetic DNA through a new enzymatic process, owned by the company, that addresses the needs of advanced therapies where DNA is the fundamental starting material. This is the case of gene therapy and mRNA-based vaccines, emerging therapeutic strategies where manufacturing is an important bottleneck. Syngoi has its own technology for the manufacture of its optimised synthetic DNA (orDNATM) which confers multiple...Read more

With the new investment fund, the managers plan to build two new plants in San Sebastian   Columbus Venture Partners already has its second fund ready to invest in companies related to health sciences. It is in the registration phase at the National Securities Market Commission (CNMV) and will be operational shortly. The expected volume is 70 million euros, reports Expansión.   According to Columbus executives, this new fund plans to provide continuity to the activity initiated by the previous one, which has five companies...Read more

Digitalisation 6 March, 2017
Subsidies brochure 2017. We are here to support your project.

This document is a simple guide, designed to quickly find information about SPRI subsidy programmes that are or will be available in...Read more

  • Share
Subscribe to our newsletter and receive it by email Write your email address here to subscribe // Subscribe

Únete a más profesionales como tú

Síguenos y recibe en tu Linkedin información diaria segmentada
por sectores de actividad y países de interés para tomar las
decisiones más competitivas

Súmate, somos una red imparable

If you weren’t able to attend

you can check out the key points on our YouTube channel

Networkingzone


Find the professionals that have
attended the same events as you.
We’re sure you’ll have so much to talk about.

Log in to your agenda.spri.eus
profile and strengthen your network

Register Log in to your profile